Epitalon
Tetrapeptide (Ala-Glu-Asp-Gly), developed at the St Petersburg Institute of Bioregulation. Activates telomerase and restores circadian rhythm. The evidence base is 30+ years of Khavinson data - impressive in depth, geographically concentrated in one research group.
Research chemicalNot WADA-listedInjectableLongevityCircadian
Key facts
Common routesSC, IM
Half-lifeShort (plasma); effects long-lasting
Typical range10 mg/day × 10 days, 2× yearly
Summary
Epitalon is a synthetic tetrapeptide - four amino acids (Alanine-Glutamate-Aspartate-Glycine) - developed by Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation as a synthetic version of the natural pineal-gland extract Epithalamin. Addresses the two intertwined problems of biological aging in Khavinson's model: telomere shortening and pineal-gland dysfunction.
The evidence base is unusual. 30+ years of Russian research, including a 12-year mortality study showing reduced cardiovascular and all-cause mortality in elderly patients. Western RCT replication is thin, however - the data is high-quality in depth, but geographically concentrated in the Khavinson group. That isn't “not real,” but it does mean the entire evidence picture comes from one source.
The Khavinson-data caveat
Most substantive human data on Epitalon comes from a single research group in St Petersburg, with publications largely in Russian journals and conferences. That isn't automatically suspect - the methods are respected in Western reviews, and the long-term mortality study has a track record few supplement-research programmes can match. But it does mean: the entire evidence picture comes from one source. Users who explicitly want Western-RCT validation won't find it.
Mechanism notes
Telomerase activation
Induces production of telomerase, the enzyme that extends the protective DNA end-caps (telomeres). Telomere shortening with each cell-division cycle is one of the central Hayflick-limit stories of cell senescence. That Epitalon activates telomerase has been confirmed in vitro in human somatic cells.
Pineal-gland restoration
Restores light-sensitivity in the pineal gland, normalising melatonin production and circadian rhythm. This is the mechanism behind the most consistent subjective user report: deeper sleep, more vivid dreams, a feeling of reset to the sleep-wake cycle during a course.
Antioxidant activity
Increases the activity of antioxidant enzymes like superoxide dismutase (SOD). Reduces oxidative stress in models - a component of the broader anti-aging story, but subtler than the telomerase and pineal effects.
Dosing patterns
Khavinson protocol (standard)
10 mg daily SC or IM for 10 days, repeated every 6 months. This is the original Russian clinical protocol the mortality studies are based on. Compared to other peptides, the daily dose is high - a 10 mg vial per day - but the cycle is short and intermittent.
Modern low-dose protocol
100–500 mcg daily over longer durations. Based on the theory that synthetic Epitalon is more potent than the original Epithalamin extract. This dosing diverges from the primary evidence base - users at this level who “feel nothing” may be running a sub-effective variation of an unproven protocol.
Cycle frequency
Traditionally twice yearly (every 6 months). Not intended for year-round use. Users running Epitalon continuously diverge from both Khavinson's data and the theoretical rationale of the protocol.
Evidence snapshot
Tier: Limited data (with caveat). Rating B - the depth of the Khavinson data is real, but the geographic concentration on one research group is a known limitation. Western peer-reviewed RCTs are scarce. Animal data (Drosophila, mouse, rat lifespan) is robust and replicated multiple times.
Human data
Khavinson mortality study: 12-year follow-up in elderly patients treated with Epithalamin (pineal extract, not synthetic Epitalon) showed significant reduction in cardiovascular and all-cause mortality vs controls. Sleep / melatonin studies showed restoration of melatonin rhythm in elderly subjects. Western replication outstanding.
Animal data
Consistent lifespan extension in Drosophila, mice, and rats across multiple studies. Anisimov 2003: Epitalon treatment reduced the incidence of spontaneous tumours in mice - counter-intuitive to the cancer-promotion concern around telomerase activation. In-vitro confirmation of telomerase induction in human somatic cells.
Safety considerations
Exceptionally clean safety record across 30+ years of Russian clinical use. No reported serious adverse events. Vivid dreams are the only consistently reported “effect” sometimes interpreted as a side effect - actually the melatonin mechanism doing its job. The theoretical cancer concern is softened by the animal data (tumour reduction, not promotion), but active malignancy remains a caution.
Common cautions
- Users running 100 mcg instead of 10 mg are dosing well below the trial data - either follow the Khavinson protocol or accept it's an “off-label” experiment
- Active malignancy is a theoretical caution (telomerase activation), despite the tumour-reducing animal data
- Data is largely from one research group - Western RCT validation isn't available; factor that into your expectations
- Don't run year-round - the intermittent twice-yearly cadence is part of the protocol, not convenience